Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has taken a new direction in its operations, which will enhance its commitment to developing critical care products. The specialty pharmaceutical company has established a definitive license agreement of collaborating with MD Anderson Cancer Center (MDACC). The collaboration aims at bringing together the duo’s efforts in commercializing Mino-Wrap. This is a liquefying gel-based wrap, and it contains minocycline and rifampin. The two are co-related in the reduction of tissue expander (TE) infections, which result from breast reconstructive surgeries.
More often than not TE infections require the complete removal of the TE. Treatment with culture-directed antibiotics follows but this does not mean that the patient is off the hook of complications. Records have it that close to 100,000 patients in the U.S. are seeking breast reconstruction procedures as a result of mastectomies.
Mino-Wrap is efficient at preventing bacterial growth on silicone surfaces
The rate of TE-related infections us approximately between 2.5% and 24%. This, however, depends on various factors such as the extent of surgery and the duration of postoperative drainage among others. A silicone TE can serve as an effective but temporary device for use in the mastectomy space. It is placed in a surgical pocket.
However, it is likely to get infections while in the pocket but according to scientists. Nonetheless, they also claim that a bioabsorbable, antimicrobial solid film wrap prevents the infection. Further studies have revealed that Mino-Wrap can prevent with ease the growth of bacteria on silicone surfaces.
Citius has been exploring unique properties of minocycline in both Mino-Wrap
“We are extremely pleased that Citius was able to secure the worldwide license for CITI 101, and to continue collaborating with MDACC,” writes the President and CEO of Citius Pharmaceuticals, Myron Holubiak.
The company has put in too much investment in the discovery of the uniqueness in Mino-Wrap and Mino-Lok. The latter in the phase 3 trials. The former is one of the many examples, which utilizes existing active pharmaceutical ingredients. Holubiak affirms that the company is looking forward to bring on board many other positive developments shortly. The mission is to obtain a market leading position.